Physician profile
Chase Spell
NPI 1932480589
$1,580.80
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,381 · 2022: $186 · 2023: $13.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mvp Orthopedics INC | $1,421.23 | 2021-2023 | |
| Bioventus LLC | $56.13 | 2021-2022 | |
| Integra Lifesciences Corporation | $33.27 | 2022 | |
| Smith+Nephew, INC. | $19.69 | 2022 | |
| Heron Therapeutics, INC. | $18.51 | 2021 | |
| Abbott Laboratories | $17.25 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.72 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Spell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.